Bridgepoint Group (LON:BPT) Raised to “Buy” at Citigroup

Bridgepoint Group (LON:BPT) was upgraded by research analysts at Citigroup to a “buy” rating in a report issued on Thursday,London Stock Exchange reports. The firm currently has a GBX 410 ($5.33) price target on the stock. Citigroup’s price objective points to a potential upside of 22.02% from the stock’s current price.

Bridgepoint Group Stock Up 1.7 %

BPT traded up GBX 5.60 ($0.07) on Thursday, hitting GBX 336 ($4.37). The company had a trading volume of 291,683 shares, compared to its average volume of 3,969,312. The company has a debt-to-equity ratio of 12.89, a quick ratio of 3.60 and a current ratio of 4.98. The stock has a market capitalization of £2.78 billion, a price-to-earnings ratio of 61.04, a P/E/G ratio of 0.61 and a beta of 1.72. The stock has a fifty day moving average price of GBX 359.12 and a 200-day moving average price of GBX 346.42. Bridgepoint Group has a 12-month low of GBX 202.40 ($2.63) and a 12-month high of GBX 410 ($5.33).

Bridgepoint Group (LON:BPT) last announced its quarterly earnings data on Thursday, March 13th. The company reported GBX 19.50 ($0.25) earnings per share for the quarter. Bridgepoint Group had a net margin of 16.74% and a return on equity of 6.10%. Analysts predict that Bridgepoint Group will post 17.4062165 EPS for the current fiscal year.

About Bridgepoint Group

Bridgepoint Group plc is a private equity and private credit firm specializing in middle market, small mid cap, small cap, growth capital, buyouts investments, syndicate debt, infrastructure, direct lending and credit opportunities in private credit investments. It prefers to invest in advanced industrials, automation, agricultural sciences, energy transition enablers, business services, financial services, professional services, testing inspection and certification, information services, consumer, digital brands, video games, wellbeing products, health care, pharma and MedTech outsourced services, pharma products, and MedTech Products sectors.